Dr. Robert J. Motzer, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Michigan Medical School (1981)
- Years since graduation
- 45
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 169
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1981Medical school: University of Michigan Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NY license 153733
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Memorial Solid Tumor Group (234 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 169
- Services billed
- 566
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 246 | 89 |
| Established patient office or other outpatient visit, 20-29 minutes | 205 | 101 |
| New patient office or other outpatient visit, 60-74 minutes | 26 | 26 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Cabometyx (cabozantinib s-malate) | 50 |
| Lenvima (lenvatinib mesylate) | 42 |
| Welireg (belzutifan) | 17 |
| Everolimus | 14 |
| Prednisone Other prescribers in New York, NY | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 4 payments worth $3,295 in total to this clinician.
| Merck Sharp & Dohme LLC | $3,295 |
|---|
| Consulting Fee | $3,295 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Jul 1, 2025 | Consulting Fee | $1,600 |
| Merck Sharp & Dohme LLC Jul 14, 2025 | Consulting FeeCompany’s descriptionProvided as part of a clinical research engagement. | $640 |
| Merck Sharp & Dohme LLC Jul 30, 2025 | Consulting Fee KEYTRUDA · ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $610 |
| Merck Sharp & Dohme LLC Jan 6, 2025 | Consulting FeeCompany’s descriptionProvided as part of a research engagement. | $445 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 4 companies. The companies reported $2,631,551 in research payments for these studies, mostly to the institutions running them.
- An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1,L1 …
Merck Sharp & Dohme LLC - A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Rena…
Merck Sharp & Dohme LLC - A Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants with RCC KEYMAKER-U03# Substudy 03C in Participants with Recurrent Disease After Anti-PD-L1 Adjuvant Therapy
Merck Sharp & Dohme LLC - A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell…
Exelixis Inc. - A Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants with RCC KEYMAKER-U03# substudy 03B in Second-Line Metastatic Participants
Merck Sharp & Dohme LLC - Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
E.r. Squibb & Sons, L.l.c. - A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
Exelixis Inc. - Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
Aveo Pharmaceuticals, Inc. · Completed · NCT04987203 - A Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants with RCC KEYMAKER-U03# Substudy 03A in First Line Metastatic Participants
Merck Sharp & Dohme LLC - A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma(CheckMate 9ER: CHECKpoint pathway …
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.